See more section
James’ practice focuses on capital markets and securities matters, as well as strategic life sciences transactions and general corporate matters.
His experience includes initial public offerings (IPOs), private investments in public equity (PIPEs), registered direct offerings (RDs), at the market offerings (ATMs), special purpose acquisition companies (SPACs), and securities laws and SEC compliance.
James also represents pharmaceutical, biotechnology, consumer healthcare, and medical device companies on strategic transactions and general corporate matters, including mergers and acquisitions, licensing, research, development and collaboration agreements, commercial agreements, and various corporate governance matters.
A former associate at an Am Law 50 firm, James also has over 12 years of prior experience at several global pharmaceutical corporations, including Merck, where he served in the Office of the General Counsel, and Novartis, where he worked in preclinical research and development.